HomeCompareITCI vs EPRT

ITCI vs EPRT: Dividend Comparison 2026

ITCI yields 1.52% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $41.5K in total portfolio value
10 years
ITCI
ITCI
● Live price
1.52%
Share price
$131.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$167.32
Full ITCI calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ITCI vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITCIEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITCI + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITCI pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITCI
Annual income on $10K today (after 15% tax)
$128.91/yr
After 10yr DRIP, annual income (after tax)
$142.22/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,772.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITCI + EPRT for your $10,000?

ITCI: 50%EPRT: 50%
100% EPRT50/50100% ITCI
Portfolio after 10yr
$42.6K
Annual income
$6,504.02/yr
Blended yield
15.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ITCI
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$98.50
-25.3% upside vs current
Range: $70.00 — $132.00
Altman Z
38.0
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITCI buys
0
EPRT buys
0
No recent congressional trades found for ITCI or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITCIEPRT
Forward yield1.52%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$21.9K$63.4K
Annual income after 10y$167.32$12,840.73
Total dividends collected$1.6K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$98.50$35.50

Year-by-year: ITCI vs EPRT ($10,000, DRIP)

YearITCI PortfolioITCI Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,852$151.66$11,205$505.18$353.00EPRT
2$11,765$153.81$12,672$682.46$907.00EPRT
3$12,745$155.85$14,490$930.48$1.7KEPRT
4$13,794$157.78$16,786$1,282.69$3.0KEPRT
5$14,920$159.61$19,753$1,791.56$4.8KEPRT
6$16,125$161.33$23,677$2,541.64$7.6KEPRT
7$17,417$162.96$29,008$3,672.99$11.6KEPRT
8$18,801$164.50$36,463$5,425.08$17.7KEPRT
9$20,283$165.95$47,238$8,221.57$27.0KEPRT
10$21,870$167.32$63,385$12,840.73$41.5KEPRT

ITCI vs EPRT: Complete Analysis 2026

ITCIStock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Full ITCI Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ITCI vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITCI vs SCHDITCI vs JEPIITCI vs OITCI vs KOITCI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.